Zenith Epigenetics Announces Publication of a Case Study From its Ongoing mCRPC Clinical Study
Zenith Capital Corp.
Sep. 04, 2018
CALGARY, Alberta, Sept. 04, 2018 (GLOBE NEWSWIRE) -- Zenith Epigenetics Ltd. (“Zenith” or the “Company”), a wholly-owned subsidiary of Zenith Capital Corp., announced today the publication of a scientific article on the effect of ZEN-3694, Zenith’s novel small molecule BET (bromodomain and extra-terminal) inhibitor, in a patient with metastatic castrate resistant prostate cancer (“mCRPC”).
Advanced Therapeutics (Wiley) published: “Modulating BET Bromodomain Inhibitor ZEN-3694 and Enzalutamide Combination Dosing in a Metastatic Prostate Cancer Patient Using CURATE.AI, an Artificial Intelligence Platform”. This study reports the clinical application of CURATE.AI, a powerful artificial intelligence platform, towards the simultaneous optimization of multi-drug dosing in a mCRPC patient. This patient was dosed with combination therapy of ZEN-3694 and enzalutamide. An individualized CURATE.AI profile was developed for the patient, showing that ZEN-3694 played a key role in mediating the low PSA levels observed in the patient and in preventing disease progression. This was further demonstrated by PSA dose response to ZEN-3694. Using CURATE.AI-suggested dosing of ZEN-3694 and enzalutamide, the patient achieved a durable response now ongoing for > 16 months.
The full report can be accessed here:
About mCRPC and ZEN-3694
mCRPC is a major unmet medical need due to its widespread occurrence and incurable status. Current standard of care for this disease is suppression of androgen signaling by androgen receptor (“AR”) antagonists and AR synthesis inhibitors. Although most patients respond to these agents, eventually all patients develop resistance and progress with no availability of subsequent standard of care therapy. Supported by extensive pre-clinical rationale, Zenith is conducting a Phase1/2 trial in mCRPC patients combining its BET inhibitor, ZEN-3694, with enzalutamide in patients that have progressed on AR antagonist therapy. Complete clinical data from this study will be presented at a future major oncology clinical conference.
The design of the ongoing clinical study can be accessed here:
Combination therapy, or the use of multiple drugs for oncology, is often administered at fixed doses for all patients. However, patients inherently respond differently from one another when given the same treatment. Furthermore, a single patient’s response to treatment evolves over time, such that the patient’s response during one week may vary dramatically the following week. There have been ongoing efforts to explore single-patient, or N=1, clinical studies to address the dynamic nature of drug synergy, since it is time-dependent, dose-dependent, and patient specific. To address the dynamic nature of synergy, CURATE.AI constructs 3-dimensional, patient-specific profiles using their own data that visually guide the continuous identification of drug doses that result in the best possible treatment response. As the patient and the disease evolve during treatment, the map evolves as well. As such, this case report describes tailored optimization of combination therapy.
Zenith Capital Corp. is a biotechnology investment company. Zenith Epigenetics Ltd., a wholly-owned subsidiary of Zenith Capital Corp., is a clinical stage biotechnology company focused on the discovery and development of novel therapeutics. Zenith Epigenetics Ltd.’s bromodomain (BET) inhibitors are being advanced in several oncology indications and have the potential to impact multiple additional diseases as well. The lead compound, ZEN-3694, is in clinical development for metastatic Castration Resistant Prostate Cancer (“mCRPC”).
For further information, please contact: Investor Relations & Communications
Zenith EpigeneticsPhone: 587-390-7865Email: firstname.lastname@example.org Website: www.zenithepigenetics.com